
jul pm et
summari compani distribut pharmaceut broad rang health care provid also
price-to-earnings oper ep
past perform indic futur perform reli upon
analysi prepar equiti analyst
jul stock trade
expect revenu fy sep expand
faster growth experienc
fy benefit increas drug
util on-board retail
acquisit rite aid store
complet march howev see
sale growth somewhat restrict slow
drug inflat increas price
expect ebitda margin declin slightli
fy fy difficult
gener drug price deflat lower
brand price inflat addit see
price sever new contract contribut
margin pressur fy howev pressur
seen somewhat off-set increas
distribut walgreen improv
purchas drug purchas joint
ventur walgreen
follow share repurchas
benefit tax reform estim
adjust ep fy
oper ep fy exclud
one-tim item period
wall street journal report februari
walgreen boot allianc made
take-over approach surpris
decis seek acquir
remain alreadi
although talk reportedli earli stage
combin make strateg sens us
reimburs pressur perman
secur relationship key drug
risk opinion target price includ
cessat potenti acquisit talk
intensifi competit loss
one major client execut risk
relat integr new walgreen
target price assum
forward ev/ebitda near high end
three-year trade rang
believ justifi potenti industri
pressur see intens price
competit slow brand gener
risk assess reflect believ strong
long-term growth prospect drug distributor
age develop popul expand middl
class around world drive growth prescript
volum also view barrier entri industri
high posit balanc view
extrem limit abil rais price current
environ custom consolid polit
aug ep estim base cfra oper earn
histor earn report compani report
stk
dividend paid sinc compani report
past perform indic futur perform
reli upon
forecast reliabl indic futur perform
redistribut reproduct prohibit without written permiss copyright cfra document intend provid person invest advic take account specif invest
object financi situat particular need specif person may receiv report investor seek independ financi advic regard suitabl and/or appropri make
invest implement invest strategi discuss document understand statement regard futur prospect may realiz investor note incom
invest may fluctuat valu invest may rise fall accordingli investor may receiv back less origin invest investor seek advic concern impact
invest may person tax posit tax advisor pleas note public date document may contain specif inform longer current use make
invest decis unless otherwis indic intent updat document
execut vice-president chief
corpor overview amerisourcebergen corp second largest pharmaceut distribut
compani share pharmaceut wholesal busi calendar year
primari busi entail wareh logist servic connect manufactur
brand-nam gener pharmaceut end-us outlet downstream custom includ wide
varieti retail mail-ord pharmaci hospit network outpati facil also offer
value-ad servic pharmaci manag consult inventori manag softwar drug
commerci servic manufactur group purchas servic physician practic
occupi strong posit specialti pharmaceut distribut especi oncology-rel
servic estim share specialti drug sale specialti busi
tradit achiev faster organ growth higher margin tradit drug distribut
busi specialti revenu grow fy versu tradit specialti achiev
consecut quarter growth fy
custom concentr import awar ten largest account total
revenu fy sale two largest custom
script esrx account revenu respect
market profil accord data iqvia hda research foundat pharmaceut sale
reach cy cy cy also saw pharmaceut sale move
distribut compani cy remaind move directli
manufactur downstream custom within industri sale specialti drug grow faster
tradit drug specialti grew cy tradit contract
result sale mix shift traditional/specialti cy cy
increas access health insur especi global middl class expand age
popul posit driver health care distribut drug price inflat deflat one
critic factor profit return wareh logist inventori data servic
larg distribut contract typic pay distributor negoti percentag purchas order
amount price often negoti manufactur downstream custom therefor rise
drug price lead larger whole dollar servic fee inflat also help distributor tradit resal
arrang purchas bulk inventori manufactur resel downstream
custom gain spread increas lower-cost exist inventori sold new higher price
big pharmaceut distributor
pursu consolid strategi recent year lead increas combin market share
cy addit gener drug sourc joint ventur jv larg retail
pharmaci becom standard began collabor jv improv
bargain power gener manufactur similar jv walgreen
respect three jv repres three largest pharmaceut
distributor retail pharmaci chain
increas bargain power manufactur like factor gener price deflat trend
last sever year contribut pharmaceut sale growth slow
respect slower growth tradit drug busi led
distributor seek higher growth margin segment specialti pharmaceut
corpor strategi focus broad strategi expand core specialti
pharmaceut distribut busi recent expans busi includ
pharmedium lead provid specialti product acut care hospit acquir
novemb novemb announc acquir smith largest privat held
drug distributor
also enter strateg relationship wherebi
becam primari distribut resourc intern pharmaci compani return
grant warrant purchas stake gradual increas ownership august
sinc launch relationship fy revenu growth materi exceed
fy particularli activ driven addit distribut busi
see potenti risk move forward howev pharmaci may ultim steer
busi away avoid send profit largest competitor
competit landscap price breadth product offer value-ad servic program
primari competit factor drug distribut industri big domin larg
multi-year contract consolid amongst downstream custom major impact
distributor earn case gain busi
pharmaci chain sold store prior transact rival provid
distribut servic store
financi trend fy achiev five-year compound annual growth rate
revenu normal ep aid stock buyback fy
also achiev highest ebitda margin last five year fy low fy
view balanc sheet strong cash billion march net debt/ebitda
redistribut reproduct prohibit without prior written permiss copyright cfra
base cfra proprietari quantit model
stock rank overvalu
analysi stock current worth base
cfra proprietari quantit model suggest
slightli under-valued
neutral sinc june technic indic
neutral
figur base fiscal year-end price
growth rate averag
lt debt capit
return equiti
balanc sheet data million
oper
long term debt capit
net incom revenu
return asset
return equiti
 global market intellig data may preliminari restat result discontinu operations/speci item per share data adjust stock dividend ep dilut
redistribut reproduct prohibit without prior written permiss copyright cfra
fundament outlook health care
distributor sub-industri next
month neutral outlook base mainli
favor demand trend see drug
suppli segment gener compris
busi three larg
drug distributor make bulk
market-cap weight sub-industri index
partial off-set drug reimburs drug
price cost pressur expect
distributor benefit new gener
result patent expir mani
large-sel brand drug view
gener import drug distributor
carri wider margin brand
product howev note drug price inflat
like continu moder
restrict gross profit dollar growth
acquisit strateg partner
sector also increas
cardin
drug-sourc contract
caremark partnership support
improv purchas cost greater drug
purchas scale support improv gener
longer term expect larg
distributor realiz high-single-digit
annual ep gain benefit gener drug
penetr age popul drug price
inflat addit see near term
benefit increas american
cover health insur
afford act make
pharmaceut afford note
recent repeal individu mandat
result fewer live cover
next year also see distributor top
line pressur next year
patent loss sever blockbust drug
base index
five-year market price perform jul
pressur fee distributor receiv
supplier
contributor margin expans
cost control divestitur
under-perform unit profit
stock benefit acquisit
april health
distributor decreas vs
declin composit
sub-industri index fell
versu gain
note sector sub-industri inform base
past perform indic futur perform
reli upon
yield equiti
ltd
peer group compani stock select issu base market capit
note peer select base global industri classif standard market capit peer group list includ compani similar characterist may includ compani within
industri and/or engag line busi
redistribut reproduct prohibit without prior written permiss copyright cfra
think valuat pressur slow ep growth
due competit industri price mar-q adjust ep vs
estim revenu growth driven strong growth
specialti distribut extend express script esrx distribut
deal fy sale fy margin widen expect
strong growth wider-margin non-distribut busi /j agnes
amerisourcebergen corpor lift
target price-to-earnings low end rang
fy sep ep estim see valuat pressur
slow ep growth due competit industri price set fy ep
estim dec-q ep vs estim
benefit receiv drug manufactur rebat earlier expect
lower tax share repurchas front-end load see
fundament benefit new commerci busi stabl drug
analyst research note compani news
et cfra keep hold opinion share
lower target price assum
forward ev/ebitda near high end trade rang
believ justifi potenti industri consolid despit
earn growth pressur see intens price competit slow
brand gener drug price inflat mar-q adjust ep vs
estim revenu grew estim
benefit recent acquisit growth largest custom
initi benefit complet
on-board retail pharmaci follow acquisit rite aid
store walgreen march margin narrow less expect benefit
recent acquisit stabil gener drug inflat rate
despit pressur suspens oper pharmedium
memphi distribut center expect becom fulli oper
fy sep /joseph agnes
et cfra keep hold recommend share
amerisourcebergen corpor lift target
ev/ebitda near high end rang
see valuat support made
take-over approach accord wall street journal
surpris decis seek acquir remain
alreadi although talk reportedli earli stage
combin make strateg sens us greater scale would help off-set
drug reimburs pressur perman secur relationship
key drug supplier /joseph agnes
corpor rais target price-to-earnings
near low end abc five-year rang fy sep ep
estim see valuat hurt intens price
competit slow drug price inflat despit benefit
acquisit strength specialti drug see fy ep growth
support tax reform benefit partial off-set
suspens activ outsourc facil lift fy ep
dec-q ep vs estim
tax benefit /joseph agnes
et cfra keep hold opinion share
lower target price-to-earnings near
low end abc rang fy sep ep estim
see valuat hurt intens price competit
slow drug price inflat despit benefit acquisit strength
specialti drug set fy ep sep-q ep vs
estim revenu rose less expect
strength specialti drug non-drug distribut busi partial
off-set lower drug inflat increas gener convers /joseph
et cfra downgrad opinion share
hold buy cut target
price-to-earnings near low end rang fy sep ep
estim cut see valuat restrict unfavor
industri drug price jun-q ep vs estim
lower tax expect revenu growth estim
restrict slow brand gener drug price inflat less
favor custom contract renew despit distribut pressur see ep
support gain consult anim health courier busi /j
et cfra keep buy opinion share
corpor keep target price-to-earnings
low end rang fy sep ep estim
note research note reflect cfra publish opinion analysi stock time note publish note reflect view equiti analyst date time
indic note may reflect cfra current view compani
redistribut reproduct prohibit without prior written permiss copyright cfra
fiscal year analyst estim earn
usd quarter fiscal year
announc earn per share usd repres
total revenu estim fiscal year
analyst estim earn per share grow
usd
total
estimate
forecast reliabl indic futur perform
note compani earn outlook play major part invest decis global market intellig organ earn estim wall street analyst
provid consensu earn next two year well earn estim chang time note inform provid relat consensu
estim intend predict actual result taken reliabl indic futur perform
note tabl graph chart report cite refer sourc sourc global market intellig
redistribut reproduct prohibit without prior written permiss copyright cfra
p/nav price net asset valu ratio price-to-earnings-to-growth ratio pv present
 research develop roce return capit employ roe
return equiti
roi return invest
 return invest capit
roa return asset
wacc weight averag capit
dividend american depositori receipt adr american depositori
share adss net tax paid countri origin
reflect equiti analyst view given compani oper risk
risk firm abil continu on-going concern qualit risk
assess rel rank star univers
reflect risk factor relat compani oper oppos risk
volatil measur associ share price etf reflect
capitalization-weight basi averag qualit risk assess
assign hold fund
star rank system definit
total return expect outperform total return relev benchmark
notabl margin come month share rise price
total return expect outperform total return relev benchmark
come month share rise price absolut basi
total return expect close approxim total return relev
benchmark come month share gener rise price
absolut basi
total return expect under-perform total return relev
benchmark come month share price anticip
total return expect under-perform total return relev
benchmark notabl margin come month share fall
price absolut basi
north america relev benchmark europ
asia relev benchmark europ asia
sinc januari cfra equiti fund research servic
predecessor capit iq equiti research rank univers
common stock adr american depositari receipt adss american
depositari share base given equiti potenti futur perform
similarli rank asian european equiti sinc june
rank equiti accord individu forecast equiti futur total
return potenti versu expect total return relev benchmark
region index asia europ
base time horizon star design meet need
investor look put invest decis perspect data use
assist determin star rank may result analyst
model well intern proprietari model result dynam data
also known
 growth
stabil earn dividend deem key element establish
global market intellig earn dividend rank common stock
design capsul natur record singl symbol
note howev process also take consider certain
adjust modif deem desir establish rank
final score stock measur score matrix determin
analysi score larg repres sampl stock
rang score array sampl align follow
ladder rank
cfra earn per share ep estim reflect analyst project futur
ep continu oper gener exclud variou item
view special non-recur extraordinari also ep estim reflect
either forecast equiti analyst consensu averag ep estim
independ compil global market intellig data
provid cfra among item typic exclud ep estim
asset sale gain impair restructur merger-rel charg legal
insur settlement process research develop expens gain
loss extinguish debt cumul effect account
chang earn relat oper classifi
compani discontinu inclus item stock option
expens recur type charg may vari depend
factor industri practic analyst judgment extent
type data disclos compani
equiti analyst project market price given secur command
month henc base combin intrins rel privat
cfra equiti research produc distribut account research
analyt llc d/b/a cfra cfra us togeth affili
subsidiari cfra certain research produc distribut standard
 poor malaysia sdn bhd cfra malaysia certain research distribut
cfra uk limit cfra uk cfra uk cfra malaysia wholly-own
subsidiari cfra us
abbrevi use equiti research report
ebit earn interest tax
redistribut reproduct prohibit without prior written permiss copyright cfra
